[Antitumor activity of navelbine (vinorelbine ditartrate), a new vinca alkaloid analog].
The antitumor activity of navelbine (vinorelbine ditartrate, KW-2307) against murine and human transplantable tumors was compared with those of other vinca alkaloids, vindesine (VDS), vincristine (VCR) or vinblastine (VLB). KW-2307 and VDS increased the life span of mice bearing ascitic tumors (P 388 leukemia, L 1210 leukemia, EL-4 lymphoma, Colon 26, FM 3 A mammary carcinoma and M 5076 sarcoma) slightly more than VCR or VLB. A significant difference was not found in the antitumor activities against 6 murine solid tumors (B 16 melanoma, Colon 26, FM 3 A mammary carcinoma, Lewis lung carcinoma, M 5076 sarcoma and Sarcoma 180). However, a remarkable difference was observed in the antitumor activities against 11 human tumors inoculated into nude mice. The activity of KW-2307 was more than those of other 3 drugs against 4 human non-small cell lung carcinomas (Lu-65, Lu-99, LC-6 and L-27) and 2 stomach carcinomas (St-4 and St-40). KW-2307 and VDS were also effective in inhibiting the growth of 2 human breast carcinomas (MX-1 and Br-10).
Ashizawa
T
T
Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Co., Ltd.
Miyoshi
K
K
Asada
M
M
Kobayashi
E
E
Okabe
M
M
Morimoto
M
M
Gomi
K
K
Hirata
T
T
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D008819:Mice, Nude; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D013274:Stomach Neoplasms / Q000188:drug therapy; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D014748:Vinca Alkaloids / Q000627:therapeutic use*; D000077235:Vinorelbine
D000970:Antineoplastic Agents; D014748:Vinca Alkaloids; D014747:Vinblastine; D000077235:Vinorelbine